AXQ Capital LP Buys Shares of 22,800 AstraZeneca PLC (NASDAQ:AZN)

AXQ Capital LP bought a new position in AstraZeneca PLC (NASDAQ:AZNFree Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,800 shares of the company’s stock, valued at approximately $1,544,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Fairfield Bush & CO. acquired a new position in AstraZeneca in the 1st quarter worth about $28,000. Panagora Asset Management Inc. increased its stake in shares of AstraZeneca by 55.1% in the first quarter. Panagora Asset Management Inc. now owns 11,956 shares of the company’s stock valued at $793,000 after buying an additional 4,249 shares during the period. BlackRock Inc. boosted its position in AstraZeneca by 22.0% during the 1st quarter. BlackRock Inc. now owns 7,466,492 shares of the company’s stock worth $495,328,000 after buying an additional 1,343,939 shares during the period. Great West Life Assurance Co. Can grew its holdings in AstraZeneca by 102.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 525 shares of the company’s stock worth $36,000 after acquiring an additional 266 shares during the last quarter. Finally, Moors & Cabot Inc. increased its position in AstraZeneca by 2.8% in the 1st quarter. Moors & Cabot Inc. now owns 10,841 shares of the company’s stock valued at $719,000 after acquiring an additional 292 shares during the period. 15.68% of the stock is owned by institutional investors.

AstraZeneca Stock Up 0.7 %

Shares of AZN stock traded up $0.44 during trading hours on Friday, reaching $64.60. The company had a trading volume of 3,966,502 shares, compared to its average volume of 8,517,289. The business has a fifty day simple moving average of $66.26 and a 200-day simple moving average of $66.09. AstraZeneca PLC has a 12 month low of $60.47 and a 12 month high of $76.56. The company has a market cap of $200.28 billion, a price-to-earnings ratio of 33.65, a price-to-earnings-growth ratio of 1.18 and a beta of 0.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 0.82 and a quick ratio of 0.64.

AstraZeneca (NASDAQ:AZNGet Free Report) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.01). AstraZeneca had a return on equity of 30.19% and a net margin of 13.00%. The firm had revenue of $12.02 billion during the quarter, compared to the consensus estimate of $12.07 billion. During the same period in the previous year, the company posted $0.69 earnings per share. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, research analysts expect that AstraZeneca PLC will post 4.06 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The firm also recently announced a Semi-Annual dividend, which will be paid on Monday, March 25th. Shareholders of record on Friday, February 23rd will be paid a $0.965 dividend. This is a positive change from AstraZeneca’s previous Semi-Annual dividend of $0.47. This represents a yield of 2.3%. The ex-dividend date is Thursday, February 22nd. AstraZeneca’s dividend payout ratio is currently 100.52%.

Wall Street Analysts Forecast Growth

AZN has been the subject of a number of analyst reports. Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating in a research report on Wednesday, January 3rd. HSBC initiated coverage on shares of AstraZeneca in a research note on Monday, December 18th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. Finally, Morgan Stanley initiated coverage on AstraZeneca in a report on Tuesday, January 23rd. They set an “overweight” rating for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from, AstraZeneca presently has an average rating of “Moderate Buy” and a consensus price target of $80.00.

Get Our Latest Analysis on AZN

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Read More

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.